3 Hrs_1777292798912_197359786.jpg&w=64&q=75)
Source:
عكس السير
Source: عكس السير
3 Hrsعكس السير
Source: عكس السير
3 HrsReady to play
Ready to play
Researchers at Stanford Medicine have developed a small, dual-function molecule designed to redirect a key protein in lymphoma cancer cells called BCL6, aiming to make cancerous cells trigger their own death. Tests in mice showed that this bifunctional molecule, named TCIP3, eliminated tumors within 11 days without noticeable side effects such as toxicity or inflammation. The molecule works by modulating BCL6 activity through recruitment of additional proteins, preventing it from blocking cell death genes and thereby promoting the destruction of cancer cells. Despite these promising results, the treatment remains experimental and requires further research before human use. Nevertheless, it represents a novel strategy that focuses on reprogramming proteins rather than merely inhibiting them.
Notice: This Is an AI-Generated Summary
Comments (0)